GoAI
Get started
Xtant Medical Holdings, Inc. logo

Xtant Medical Holdings, Inc.

XTNT

AMEXHealthcareMedical - Devices

Open in GoAI

Previous close

$0.3249

−$0.0084 · -2.52%

Aug 21, 4:00 PM ET

XTNT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

79

Undervalued

Momentum

18

Strong Down

Sentiment

46

Mixed

Risk resilience

43

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US

Market position

Day range

Current $0.3249

52-week range

Current $0.3249

Open
$0.34
Previous close
$0.3333
Volume
143.64K
Market cap
45.57M USD
50-day average
$0.4126
-21.26% below average
200-day average
$0.5524
-41.18% below average

Financials

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends71%40%9%-22%Gross margin, FY2021: 58.79%Gross margin, FY2022: 55.44%Gross margin, FY2023: 60.75%Gross margin, FY2024: 58.17%Gross margin, FY2025: 62.92%Operating margin, FY2021: -6.97%Operating margin, FY2022: -11.65%Operating margin, FY2023: -11.13%Operating margin, FY2024: -10.30%Operating margin, FY2025: 5.44%Net margin, FY2021: -8.77%Net margin, FY2022: -14.64%Net margin, FY2023: 0.72%Net margin, FY2024: -14.03%Net margin, FY2025: 3.71%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 58.79%. Gross margin FY2022 55.44%. Gross margin FY2023 60.75%. Gross margin FY2024 58.17%. Gross margin FY2025 62.92%. Operating margin FY2021 -6.97%. Operating margin FY2022 -11.65%. Operating margin FY2023 -11.13%. Operating margin FY2024 -10.30%. Operating margin FY2025 5.44%. Net margin FY2021 -8.77%. Net margin FY2022 -14.64%. Net margin FY2023 0.72%. Net margin FY2024 -14.03%. Net margin FY2025 3.71%.

Income trends

Revenue

133.93M USD+14.21%

Operating income

7.28M USD+19.36M USD

Net income

4.97M USD+21.42M USD
Income trends across reported periods148.96M USD88.81M USD28.66M USD−31.49M USDRevenue, FY2021: 55.26M USDRevenue, FY2022: 57.97M USDRevenue, FY2023: 91.3M USDRevenue, FY2024: 117.27M USDRevenue, FY2025: 133.93M USDOperating income, FY2021: −3.85M USDOperating income, FY2022: −6.76M USDOperating income, FY2023: −10.16M USDOperating income, FY2024: −12.07M USDOperating income, FY2025: 7.28M USDNet income, FY2021: −4.85M USDNet income, FY2022: −8.49M USDNet income, FY2023: 660K USDNet income, FY2024: −16.45M USDNet income, FY2025: 4.97M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 55.26M USD. Revenue FY2022 57.97M USD. Revenue FY2023 91.3M USD. Revenue FY2024 117.27M USD. Revenue FY2025 133.93M USD. Operating income FY2021 −3.85M USD. Operating income FY2022 −6.76M USD. Operating income FY2023 −10.16M USD. Operating income FY2024 −12.07M USD. Operating income FY2025 7.28M USD. Net income FY2021 −4.85M USD. Net income FY2022 −8.49M USD. Net income FY2023 660K USD. Net income FY2024 −16.45M USD. Net income FY2025 4.97M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue133.93M USD117.27M USD91.3M USD57.97M USD55.26M USD
Cost of goods sold49.65M USD49.05M USD35.84M USD25.83M USD22.77M USD
Gross profit84.27M USD68.22M USD55.47M USD32.14M USD32.49M USD
Research and development2.1M USD2.39M USD1.34M USD915K USD870K USD
Selling, general, and administrative74.89M USD77.91M USD64.29M USD37.98M USD35.47M USD
Operating expenses76.99M USD80.29M USD65.63M USD38.89M USD36.34M USD
Interest income94K USD—149K USD31K USD—
Interest expense3.67M USD4.16M USD2.94M USD1.69M USD995K USD
Depreciation and amortization5.22M USD4.22M USD3.17M USD1.3M USD1.34M USD
Operating income7.28M USD−12.07M USD−10.16M USD−6.76M USD−3.85M USD
Net income4.97M USD−16.45M USD660K USD−8.49M USD−4.85M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
0.03
FY2025
Latest fiscal-year revenue
133.93M USD
FY2025 · +14.21% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.05-0.02-0.08-0.14FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend141.79M110.33M78.86M47.4MFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$1.50

361.68% upside
Past 12 months12-month forecastHigh $1.50Average $1.50Low $1.50

Recent analyst actions

1 institution

XTNT news

seekingalpha.com

Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript

Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript

Read source
prnewswire.com

Xtant Medical Reports Second Quarter 2026 Financial Results

Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures Company to host investor conference call and webcast today, August…

Read source
prnewswire.com

Xtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026

BELGRADE, Mont., Aug. 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced…

Read source
prnewswire.com

Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference

BELGRADE, Mont., Aug. 4, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced…

Read source

XTNT peers

National HealthCare Corporation logo

NHC

National HealthCare Corporation

$233.4

-1.41%

Perspective Therapeutics, Inc. logo

CATX

Perspective Therapeutics, Inc.

$3.30

+2.80%

Electromed, Inc. logo

ELMD

Electromed, Inc.

$39.45

-1.38%

Lineage Cell Therapeutics, Inc. logo

LCTX

Lineage Cell Therapeutics, Inc.

$1.08

0.00%

InfuSystem Holdings, Inc. logo

INFU

InfuSystem Holdings, Inc.

$12.21

+0.08%

Protalix BioTherapeutics, Inc. logo

PLX

Protalix BioTherapeutics, Inc.

$2.38

0.00%

ETFs holding XTNT

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
644.38K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
221.49K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research XTNT

research.disclaimer